The level of serum PON1 and oxLDL in dyslipidemia patients before and after 3 months of atorvastatin treatment

Abstract

The aim of our study was to investigate the effects of atorvastatin treatment on serum PON1, oxLDL, ApoA-1 and ApoB levels, which are etiologic factors, in arteriosclerosis pathogenesis. Our study was comprised of 33 hyperlipidemia patients and 24 healthy controls. Blood samples were collected before and after 3 months of atorvastatin treatment. After treatment, ApoB levels (0.88 ± 0.24 g/L) were found to be significantly lower (p < 0.001), whereas PON1 (61.7 ± 25.2 U/mL) and apoA-1 levels (1.53 ± 0.18 g/L) found to be significantly higher (p < 0.001) in comparison with the levels before treatment (1.26 ± 0.2 g/L, 46.7 ± 16.3 U/mL and 1.43 ± 0.2 g/L, respectively) . We did not find any significant difference in oxLDL levels. As a result, atorvastatin treatment may result in favorable lipid profiles in the protection against arteriosclerosis.